Recombinant Bovine Somatotropin vs Blue Dye 1: which is worse?

What is Recombinant Bovine Somatotropin?

Recombinant bovine somatotropin (rBST) is the synthetic version of bovine growth hormone (BST), naturally produced by the pituitary gland in cattle. The recombinant version is produced using genetically engineered bacteria and is injected into dairy cows to increase milk production by 10-15%. Brand name: Posilac.

What is Blue Dye 1?

Blue Dye 1 (Brilliant Blue FCF) is a synthetic blue triarylmethane dye derived from petroleum. It produces a brilliant sky-blue color and is highly water-soluble. Unlike the azo dyes (Red 40, Yellow 5/6), Blue 1 belongs to the triarylmethane chemical class.

Documented risks

Recombinant Bovine Somatotropin: See recombinant-bovine-growth-hormone-rbgh for full detail. Key concerns: rBST elevates IGF-1 in milk; elevated blood IGF-1 is associated with breast, prostate, and colorectal cancer risk in epidemiological studies. Animal welfare: increased mastitis (up to 25-50% higher rates), lameness, and antibiotic use. The Codex Alimentarius Commission declined to endorse rBST safety MRLs in a historic 33-29 vote. Health Canada rejected rBST approval in 1999 after finding it caused significant animal health problems requiring increased antibiotic use.

Blue Dye 1: Blue Dye 1 was historically banned in several European countries before EU harmonization permitted it (as E133). EFSA's 2010 comprehensive safety re-evaluation found no evidence of carcinogenicity in standard animal tests. The ADI was set at 6 mg/kg body weight. The most significant documented safety concern for Blue 1 involves intravenous/enteral administration rather than dietary intake. In 2003, the FDA issued a Public Health Advisory warning against using Blue 1 (used as a food coloring agent in enteral nutrition formulas to detect aspiration in critically ill patients) after multiple case reports — including deaths — documented that Blue 1 can be absorbed through damaged intestinal mucosa and cause cardiovascular instability, metabolic acidosis, and death. The FDA advisory specifically warned against this clinical use in intensive care patients. This is a medical use concern, not a dietary intake concern. For healthy consumers eating normally, EFSA found no significant safety concerns at food use levels. Blue 1 was not included in the 2007 Lancet hyperactivity study. However, it falls under the FDA's April 2025 announcement to phase out all petroleum-based synthetic food dyes, reflecting updated policy on the class as a whole rather than specific Blue 1 data. Historically, Blue 1 was banned in multiple European countries due to safety concerns, though EU harmonization later permitted it with E-number labeling requirements. This history suggests precautionary concern even when formal regulatory action was not sustained.